Shandong Luoxin Pharmaceutical Group Co., Ltd. and Austria Marinomed signed a license Agreement on October 20th, 2021 to introduce Budesolv (budesonide solution nasal spray), which will grant Shandong Luoxin the exclusive right to develop, manufacture and commercialize the product in Greater China (including Chinese mainland, Hong Kong and Macau Special Administrative regions and Taiwan).
罗欣药业：引进布地奈德溶液型鼻喷剂产品
Luoxin Pharmaceutical Co., Ltd.: introduction of budesonide solution nasal spray products
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.